A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer.
The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.

Start Date12 Dec 2025

Sponsor / Collaborator

Merck Sharp & Dohme LLC

[+1]

NCT06833073

/ RecruitingPhase 2

A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder.
The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer.
The goal of this study are to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone.

Start Date11 Mar 2025

Sponsor / Collaborator

Merck Sharp & Dohme LLC

[+1]

NCT06295809

/ TerminatedPhase 2/3

A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)

This is a two-part (Phase 2/Phase 3) study of intismeran autogene, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC). Phase 2 has three arms intismeran autogene plus pembrolizumab given as neoadjuvant and adjuvant treatment with standard of care (SOC), standard of care (surgical resection with/without adjuvant radiation therapy (RT) only at investigator's discretion) and pembrolizumab monotherapy given as neoadjuvant and adjuvant treatment with SOC. This phase will assess the safety and efficacy of intismeran autogene in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC as compared to standard of care SOC only. The primary hypothesis is that intismeran autogene plus pembrolizumab with SOC is superior to SOC only with respect to event free survival (EFS) as assessed by the investigator. Phase 3 expansion will be determined by prespecified Go-No-Go decision in which 412 additional participants will be randomized to intismeran autogene plus pembrolizumab with SOC and SOC only, without changing the inclusion/exclusion criteria for the additional enrollment or study endpoints.
As of Amendment 04, enrollment was stopped and there will be no Phase 3 expansion.

Start Date18 Apr 2024

Sponsor / Collaborator

Merck Sharp & Dohme LLC

[+1]

100 Clinical Results associated with Intismeran Autogene

100 Translational Medicine associated with Intismeran Autogene

100 Patents (Medical) associated with Intismeran Autogene

Literatures (Medical) associated with Intismeran Autogene

01 Sep 2026·Annals of thoracic surgery short reports

Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer

Article

Author: Wang, Zheng ; Bestvina, Christine M ; Shariati, Nazly ; Spicer, Jonathan D ; Lee, Jay M ; Banerjee, Joydeep K ; Cascone, Tina ; Marron, Thomas U ; Peters, Solange ; Keller, Steven M ; Chaft, Jamie E ; Gainor, Justin F ; Deng, Xuan ; Ojalvo, Laureen S ; Khattak, Muhammad A

Background:

Neoantigens are immunogenic molecules arising from patient-specific tumor mutations. Intismeran autogene (intismeran; formerly V940, mRNA-4157), an mRNA-based individualized neoantigen therapy (INT) encoding ≤34 neoantigens unique to each patient's tumor, is designed to promote an antitumor immune response. In early-phase studies, adjuvant intismeran plus pembrolizumab showed antitumor activity with solid tumors. Standard-of-care therapy for non-small cell lung cancer (NSCLC) tumors ≥4 cm includes platinum-based chemotherapy and pembrolizumab given after (adjuvant) or both before and after (perioperative) surgical resection. We describe study designs for the INTerpath-002 and INTerpath-009 studies evaluating the addition of intismeran to adjuvant pembrolizumab-based therapy in stage II-IIIB (N2) NSCLC.

Methods:

INTerpath-002 and INTerpath-009 are randomized, double-blind, phase 3 trials. Eligible participants for INTerpath-002 have completely resected, margin-negative, stage II-IIIB (N2) NSCLC (American Joint Committee on Cancer staging manual, eighth edition) and have received 1 to 4 cycles of adjuvant platinum-based chemotherapy. Eligible participants for INTerpath-009 have resectable stage II-IIIB (N2) NSCLC and have received ≤4 cycles of neoadjuvant pembrolizumab plus chemotherapy every 3 weeks. Participants with tumors that do not achieve a pathologic complete response, per pathologic examination of the resected tumor specimen, and have R0-R1 resection are eligible for randomized treatment. In both studies, participants are randomized 1:1 to receive pembrolizumab intravenously every 6 weeks plus either intismeran intramuscularly every 3 weeks or placebo. The primary endpoint in both studies is disease-free survival per investigator.

Results:

Recruitment is ongoing for both studies.

Conclusions:

Results from these studies will provide insight into the potential role of INT in NSCLC.

01 May 2026·Translational Oncology

Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation

Review

Author: Le Tourneau, Christophe ; Filippini, Daria Maria

Head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy, with limited survival improvements despite recent advances with immune checkpoint inhibitors (ICIs). Within this context, personalized neoantigen vaccines and HPV-targeted therapeutic vaccines are emerging as innovative strategies aimed at enhancing antitumor immunity. Personalized vaccines exploit tumor-specific mutational landscape to generate highly individualized T cell responses, demonstrating favorable safety profiles and durable immunogenicity in early-phase trials. Compounds such as TG4050, mRNA-4157, and PGV001 have shown early, hypothesis-generating signals of activity (from small early-phase studies), particularly in the adjuvant setting. HPV-targeted vaccines, including PDS0101, BNT113, and CUE-101, are being explored in HPV-positive HNSCC, mainly in combination with ICIs. While some early clinical activity has been observed, these signals should be interpreted cautiously given limited sample sizes, heterogeneous populations, and exploratory endpoints in many studies, and randomized trials such as ISA101b have failed to show survival benefits over ICIs alone. Overall, therapeutic vaccination appears safe and immunologically active, yet its efficacy is constrained by the immunosuppressive tumor microenvironment. The greatest clinical potential of therapeutic vaccination may lie in earlier disease stages, where the tumor burden is lower and immune modulation more feasible. Further clinical and translational research is needed to define the optimal integration of vaccine-based therapies into multimodal treatment paradigms for HNSCC.

01 Nov 2024·Cancer Discovery

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Article

Author: Coder, Brandon ; Sun, Jing ; Chen, Xing ; Morrissey, Manju ; Gainor, Justin F. ; Weber, Jeffrey S. ; Feldman, Igor ; Hou, Peijie ; Aanur, Praveen ; Bauman, Julie E. ; Gerbereux, Lauren ; Clarke, Jeffrey M. ; Scott, Aaron J. ; Sehgal, Vasudha ; Daghestani, Hikmat N. ; Meehan, Robert ; Tasneem, Moomal ; Julian, Ricklie ; Srinivasan, Lakshmi ; Kirtane, Kedar ; Porichis, Filippos ; Pollard, Jack Russella ; Gutierrez, Martin ; Zheng, Wei ; Frederick, Joshua P. ; Burris, Howard A. ; Robert-Tissot, Celine ; Brown, Michelle ; Geiger, Jessica L. ; Patel, Manish R. ; Laino, Andressa

Abstract:

mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens to induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of mRNA-4157 via characterization of T-cell responses to neoantigens from the first-in-human, phase 1, KEYNOTE-603 study (NCT03313778) in patients with resected non–small cell lung cancer (Part A: 1-mg mRNA-4157, n = 4) or resected cutaneous melanoma (Part D: 1-mg mRNA-4157 + 200-mg pembrolizumab, n = 12). Safety, tolerability, and immunogenicity were assessed. All patients experienced ≥1 treatment-emergent adverse event; there were no grade 4/5 adverse events or dose-limiting toxicities. mRNA-4157 alone induced consistent de novo and strengthened preexisting T-cell responses to targeted neoantigens. Following combination therapy, sustained mRNA-4157-induced neoantigen-specific T-cell responses and expansion of cytotoxic CD8 and CD4 T cells were observed. These findings show the potential of a novel mRNA individualized neoantigen therapy approach in oncology.

Significance::

The safety and immunogenicity results from this phase 1 study of mRNA-4157 as adjuvant monotherapy or combination therapy with pembrolizumab show generation of de novo and enhancement of existing neoantigen-specific T-cell responses and provide mechanistic proof of concept to support further development of mRNA-4157 for patients with resected solid tumors.See related commentary by Berraondo et al., p. 2021

193

News (Medical) associated with Intismeran Autogene

09 Sep 2026

·allsci.com

BioNTech ends autogene cevumeran Phase II after OS imbalance favors control

The BNT122-01 Phase II trial of autogene cevumeran in resected colorectal cancer has been terminated after an independent data safety monitoring board identified a numerical imbalance in overall survival favoring the control arm — a finding that goes beyond the futility signal the board had flagged in October 2025 and raises more substantive questions about the vaccine's efficacy in this setting. BioNTech SE (Nasdaq: BNTX) announced the decision in consultation with Genentech, a member of the Roche Group, which co-develops the drug. The trial enrolled patients with circulating tumor DNA (ctDNA)-positive, surgically resected Stage II (high risk) or Stage III colorectal cancer (CRC) and compared autogene cevumeran as adjuvant monotherapy against watchful waiting — the current standard of care. When the data safety monitoring board (DSMB) crossed the futility boundary in October 2025, it concluded the data were too immature to support reliable efficacy conclusions and did not recommend stopping the trial. At its most recent review, the DSMB found the numerical OS imbalance and determined that further continuation was unlikely to change the outcome. No new safety signals were identified. BioNTech said full trial data will be shared with the scientific community at a future date; the magnitude, statistical significance, and causes of the OS imbalance have not been disclosed. Autogene cevumeran is a uridine mRNA–lipoplex nanoparticle vaccine encoding patient-specific tumor neoantigens identified through tumor sequencing, designed to train T cells to recognize and attack residual cancer cells. The monotherapy design in BNT122-01 was a deliberate test of whether the vaccine alone, without checkpoint inhibitor support, could prevent recurrence in a molecularly selected population. The failure reflects a well-established immunological obstacle. CRC is predominantly microsatellite stable (MSS), a subtype characterized by low mutational burden and an immunosuppressive tumor microenvironment that has consistently resisted checkpoint inhibition. Using ctDNA positivity as a selection biomarker was intended to enrich for patients at highest recurrence risk, but that enrichment strategy could not overcome the fundamental immunological hostility of MSS CRC to T cell-based approaches. The OS imbalance, if confirmed in the final analysis, would represent a more concerning outcome than futility alone. The termination is the second discontinuation for autogene cevumeran in a solid tumor indication outside pancreatic cancer. Earlier in 2026, BioNTech and Roche discontinued the Phase II IMcode004 trial evaluating autogene cevumeran plus nivolumab in adjuvant muscle-invasive urothelial carcinoma, citing a rapidly shifting treatment landscape. The pancreatic ductal adenocarcinoma (PDAC) program remains the asset's primary clinical rationale. The Phase II IMcode003 trial evaluating autogene cevumeran in combination with Roche's Tecentriq (atezolizumab) and mFOLFIRINOX chemotherapy in adjuvant PDAC is unaffected and continues as planned. That trial's combination design directly addresses the limitation exposed in BNT122-01: pairing the vaccine with checkpoint inhibition and cytotoxic chemotherapy to overcome the immunosuppressive microenvironment rather than relying on the vaccine alone. Phase I data in resected PDAC showed persistent neoantigen-specific T cell responses at three years and longer recurrence-free survival in vaccine responders, supporting the biological rationale for the combination approach. The BNT122-01 result arrives against a backdrop of mixed signals for the personalized mRNA vaccine field. Moderna and Merck's Phase III INTerpath-001 trial of intismeran autogene (mRNA-4157) plus Merck's Keytruda (pembrolizumab) met its primary and a key secondary endpoint in resected Stage IIB-IV melanoma — a result achieved in a combination setting with checkpoint inhibition. That success, and the failure in BNT122-01, together reinforce the view that personalized mRNA vaccines require immune priming support to deliver clinical benefit, particularly in immunologically cold tumor types. In adjuvant PDAC, Boston-based Elicio Therapeutics (Nasdaq: ELTX) reported in June 2026 that its off-the-shelf KRAS peptide vaccine ELI-002 7P missed its primary endpoint in the intent-to-treat population, though a post-hoc analysis in completely resected patients suggested a disease-free survival benefit. BioNTech said it will conduct a thorough analysis of the BNT122-01 data to inform future development strategy for mRNA cancer immunotherapies in immunologically cold tumor types. Chief Medical Officer Prof. Özlem Türeci said the outcome "provides scientific insight into the challenges of treating immunotherapy-insensitive tumor types with immune-suppressive microenvironments." Spot something wrong? Report an issue with this article

VaccineClinical ResultImmunotherapyPhase 2Phase 3

27 Aug 2026

·firstwordpharma.com

Fresh off a cancer vaccine win, Moderna moves to raise $2B

Moderna says it intends to offer $2 billion of convertible senior notes due in 2032, with the proposed private placement coming just over a week after positive Phase III data for its personalised mRNA cancer vaccine sent company shares soaring.Proceeds will go toward investing in its emerging oncology business and repaying debt. The offering could also be increased by another $300 million if initial purchasers exercise an option.Company shares were down around 5% following the announcement Thursday, as investors digested the proposed financing on the heels of the positive INTerpath-001 readout with partner Merck & Co. last week that sent Moderna's stock up 177%. The Phase III trial found that intismeran autogene (V940/mRNA-4157) plus Keytruda (pembrolizumab) significantly improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone in patients with completely resected stage IIB-IV melanoma.Those results could pave the way for a potential first-ever approval of a personalised cancer vaccine and have boosted investor expectations about Moderna's oncology pipeline (see – Spotlight On: mRNA breaks from vaccine stable as Moderna, Merck & Co. deliver breakthrough melanoma results and Vital Signs: Has Merck & Co. already plugged its Keytruda hole?).Moderna said the notes will not bear regular interest and will be convertible into cash, Moderna shares or a combination of the two, with final terms to be determined when the offering is priced. It also expects to enter into capped-call transactions in a bid to reduce potential dilution from conversion. The initial cap price is expected to represent a premium of at least 150% over Moderna's stock price at pricing.

VaccinePhase 3Clinical ResultmRNA

19 Aug 2026

·www.fiercebiotech.com

Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push

Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival (RFS) when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win sets the partners up to potentially seek accelerated approval. The INTerpath-001 trial enrolled 1,137 patients who had previously had their cutaneous melanoma surgically removed. These patients either received intismeran autogene—alternatively known as V940 or mRNA-4157—along with Keytruda, or Keytruda alone. The companies didn't provide specific data this morning, but did say that the improvements in both RFS as well as a secondary endpoint of prolonging survival without a distant metastasis had been “statistically significant and clinically meaningful.” The partners observed no new safety signals in the trial, according to the Aug. 19 release. Intismeran is customized for each patient, providing mRNA instructions to help the immune system hunt down as many as 34 different targets found on a patient’s tumors. “For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational,” Moderna CEO Stéphane Bancel said in the release. “We are now helping turn that vision into a reality.” The results come from a preplanned interim analysis, with the trial now set to continue so that overall survival can be analyzed down the line. In the meantime, the companies said they plan to present the trial data at an upcoming international medical meeting, as well as “engage with regulators on filing submissions for intismeran autogene in combination with Keytruda.” Speaking to investors during a second quarter earnings call last month, Moderna President Stephen Hoge, M.D., said that a positive interim readout “would obviously make the case for an accelerated review.” Moderna previously sought accelerated approval for the cancer vax in 2024, but was rebuffed by the FDA. “These first phase 3 findings for intismeran in combination with Keytruda as adjuvant therapy reinforce the promise of a more personalized approach to cancer treatment,” Dean Li, M.D., Ph.D., president of Merck Research Laboratories, said in this morning's release. “We believe individualized neoantigen therapies have the potential to redefine how patients with completely resected stage IIB-IV melanoma are treated.” In a note to investors yesterday, analysts from Citi suggested that a statistically significant RFS hazard ratio equal to or below 0.72 would be “positive,” with a figure at or below 0.65 “representing a clear win.” A ratio of 0.65 would mean the experimental treatment combo reduced the risk of recurrence by 35% compared to Keytruda and placebo. In an earlier phase 2 trial , intismeran posted an RFS hazard ratio of 0.51 at the five-year mark, though the Citi analysts noted yesterday that “some compression” from this number would be expected given the phase 3 study’s broader patient population and the possibility of disease recurrence before intismeran reaches patients. Meanwhile, Jefferies analysts offered their own take last month, suggesting that an RFS hazard ratio between 0.5 and 0.8 “should be meaningful,” with positive results likely boding well for intismeran’s slew of other ongoing phase 2 and 3 trials in a variety of solid tumors. The melanoma win follows Moderna’s triumphant recent approval for the first-ever mRNA flu vaccine, which came after the FDA initially—and controversially—refused to review the biotech’s application. The pioneering mRNA company’s oncology chief told Fierce last year that Moderna was focusing more on its cancer pipeline in the wake of the Trump administration’s more skeptical attitude to vaccines. Citi analysts wrote yesterday that Moderna’s pipeline is “still largely a show-me story.” A “clean result” for intismeran would bolster confidence in the company's strategy, the analysts suggested, “although broader execution and commercial questions would remain.”

100 Deals associated with Intismeran Autogene

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-small cell lung cancer stage I	Phase 3	United States	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Japan	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Australia	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Brazil	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Canada	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Chile	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	France	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Germany	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Greece	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Hungary	Merck Sharp & Dohme LLC	04 May 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03897881 (KEYNOTE-942, ASCO2026)	Phase 2	Melanoma	157	intismeran + pembro	ytrclxvvxr(cpgvtjgqzb) = siuufprddf iftscowgbw (mcquvcftyp, 56.3 - 78.3) View more	Positive	29 May 2026
				pembro	ytrclxvvxr(cpgvtjgqzb) = guxxukjmys iftscowgbw (mcquvcftyp, 33.3 - 63.0) View more
ASCO2026	Phase 1/2	Melanoma Adjuvant	7	Intismeran autogene + pembrolizumab	kdmztgwccf(clkgthpbey) = hzacvoqjyw kwpgrkbcox (psourxpnog ) View more	Positive	29 May 2026
NCT07221474 (INTerpath-013, ASCO2026)	Phase 2	Squamous non-small cell lung cancer First line	180	Pembrolizumab + carboplatin + (paclitaxel or nab-paclitaxel) + Intismeran autogene	melkqkwgmg(fxownwhtqz) = ozzvjmortc ltrmciybki (ulzabbvhje, 43 - 67)	Positive	29 May 2026
				Pembrolizumab + carboplatin + (paclitaxel or nab-paclitaxel) + placebo	melkqkwgmg(fxownwhtqz) = vptbmvnquh ltrmciybki (ulzabbvhje, 36 - 64)
NCT03897881 (KEYNOTE-942 \| mRNA-4157-P201, NEWS) Manual	Phase 2	Melanoma	157	intismeran autogene + KEYTRUDA	ijnrzunxif(gbamgzespg): HR = 0.510 (95.0% CI, 0.294 - 0.887) Met	Positive	20 Jan 2026
				KEYTRUDA
NCT03313778 (KEYNOTE-603, Pubmed \| Cancer Discov) Manual	Phase 1	Resectable Lung Non-Small Cell Carcinoma \| Melanoma, Cutaneous Malignant	16	mRNA-4157 (resected non-small cell lung cancer)	oaymjfqsej(sutzafihai) = All patients experienced ≥1 TEAE. uidgzkfmge (jdvgdgmiir ) View more	Positive	01 Nov 2024
				mRNA-4157 + pembrolizumab (resected cutaneous melanoma)
NCT03897881 (mRNA-4157-P201 (KEYNOTE-942), ESMO2024)	Phase 2	Melanoma	16	mRNA-4157 + pembrolizumab	gnrjuxkmoy(nilaiwumwn) = qwjttkefrk gdjjybvwpl (gqknacfzvn )	Positive	14 Sep 2024
NCT03897881 (KEYNOTE-942, ASCO2024) Manual	Phase 2	Melanoma	-	mRNA-4157 + pembrolizumab	owxvlysuao(jvnffjxrti) = lbgpzhfzkt ricwtdfjeb (ukwujghfmq ) View more	Positive	02 Jun 2024
				Pembrolizumab	owxvlysuao(jvnffjxrti) = kjrlnfshmi ricwtdfjeb (ukwujghfmq ) View more
NCT03313778 (mRNA-4157-P101/KEYNOTE-603, AACR2024) Manual	Phase 1	Squamous Cell Carcinoma of Head and Neck	22	mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro)	gqskvjshtp(folnlytags) = Most adverse events (AEs) related to INT were grade 1-2; most common were influenza-like illness, injection site pain, and pyrexia. wzmoawgevj (vjzrewupmg ) View more	Positive	05 Apr 2024
NCT03897881 (KEYNOTE-942, Pubmed \| Lancet) Manual	Phase 2	Melanoma Adjuvant	157	mRNA-4157 plus pembrolizumab	ssriwnkrox(mleylwutoo) = xqkbfikwaf nzlrhwedop (kwnbyzmqcp, 69.0 - 85.6) View more	Positive	18 Jan 2024
				pembrolizumab monotherapy	ssriwnkrox(mleylwutoo) = ukgvvhhkkv nzlrhwedop (kwnbyzmqcp, 46.9 - 76.3) View more
NCT03897881 (mRNA-4157-P201 \| KEYNOTE-942, Corporate Publications) Manual	Phase 2	Melanoma	157	mRNA-4157 + KEYTRUDA	vglbkzorxu(qkaycqtpxo) = mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% oajzigdvqm (gpveqppdqn ) View more	Positive	14 Dec 2023
				KEYTRUDA

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis